KPV (10 mg Vial)

KPV Research Chart

KPV is studied at 200 mcg–500 mcg daily in educational research settings, often used in short anti-inflammatory studies. A 10 mg vial prepared with bacteriostatic water yields about 3.33 mg/mL. This information is for research and educational use only.

KPV (Lysine–Proline–Valine) is a C-terminal tripeptide fragment of α-melanocyte-stimulating hormone (α-MSH) studied for its potential anti-inflammatory properties without melanotropic side effects. Research demonstrates KPV reduces pro-inflammatory cytokines in models of inflammatory bowel disease and systemic inflammation. This educational material presents a once-daily subcutaneous approach using a practical dilution for precise measurements.

Research context: For evidence on mechanisms, human and preclinical research, limitations, and safety, read KPV Peptide: Benefits, Uses, Side Effects, Research.

Educational guide for preparation and daily research use

Standard / Gradual Approach (3 mL = ~3.33 mg/mL)

Week	Daily Amount	Units (per administration)
Week 1	200 mcg	6 units (0.06 mL)
Week 2	300 mcg	9 units (0.09 mL)
Week 3	400 mcg	12 units (0.12 mL)
Weeks 4–8	500 mcg	15 units (0.15 mL)

Frequency: Apply once daily subcutaneously. This schedule uses the largest practical dilution (3.0 mL) to maintain manageable application volumes. For ≤10-unit (≤0.10 mL) administrations, consider 30- or 50-unit insulin syringes for improved readability and more precise measurements.

Preparation Steps

Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

Plan based on an 8–16 week daily research schedule with gradual progression.

Concise summary of the once‑weekly regimen.

Goal: Support reduction of systemic inflammation and modulate immune responses without melanotropic effects.
Schedule: Daily subcutaneous applications for 8–12 weeks (extend to 16 weeks if desired).
Amount Range: 200–500 mcg daily with gradual weekly progression.
Preparation: 3.0 mL per 10 mg vial (~3.33 mg/mL) for accurate measurements.
Storage: Lyophilized frozen at −20 °C (−4 °F) or below; prepared solution refrigerated at 2–8 °C (35.6–46.4 °F); avoid repeated temperature changes.

Suggested daily progression approach.

Start: 200 mcg daily; increase by ~100 mcg weekly as tolerated.
Target: 400–500 mcg daily by Weeks 4–8 for maintenance research observations.
Frequency: Once per day (subcutaneous).
Cycle Length: 8–12 weeks; optional extension to 16 weeks under monitoring.
Timing: Any consistent time; rotate application areas systematically.

Proper storage preserves peptide quality and stability.

Lyophilized: Store at −20 °C (−4 °F) or below in dry, dark conditions; protect from moisture and light.
Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within approximately 30 days.
Allow vials to reach room temperature before opening to minimize condensation uptake.
Avoid freeze–thaw cycles: Do not refreeze prepared peptide solutions; prepare aliquots if long-term storage is needed.

Practical considerations for consistency and safety.

Use new sterile insulin syringes for each administration; dispose in a sharps container immediately after use.
Rotate application sites systematically (abdomen, thighs, upper arms) at least 1–2 inches apart to reduce local irritation and prevent lipohypertrophy.
Apply slowly; wait a few seconds before withdrawing the needle to prevent solution backflow.
Document daily amount, application site, and any observations to maintain consistency and track tolerability.
If application-site reactions (redness, mild swelling) occur, apply a cool compress and monitor; persistent reactions warrant professional review.

KPV is the C-terminal tripeptide sequence (residues 11–13) of α-melanocyte-stimulating hormone (α-MSH), retaining potent anti-inflammatory activity without the hormone’s melanotropic effects. Preclinical studies demonstrate KPV reduces pro-inflammatory cytokines (TNF-α, IL-6, IL-1β) and modulates immune cell activity in models of inflammatory bowel disease, colitis, and systemic inflammation. The peptide’s mechanism involves inhibition of nuclear factor kappa B (NF-κB) signaling and modulation of inflammatory mediator release. Subcutaneous administration provides systemic delivery with rapid absorption and sustained anti-inflammatory effects observed in daily research protocols.

Observations from preclinical and early-stage research.

Anti-inflammatory activity: Reduces pro-inflammatory cytokines and modulates immune responses in models of inflammatory bowel disease and systemic inflammation.
Oral and subcutaneous efficacy: Multiple routes of administration show activity, with subcutaneous delivery demonstrating consistent bioavailability.
Wound healing support: Preclinical data suggest KPV may support tissue repair and wound healing processes through inflammatory modulation.
Generally well tolerated: Occasional mild reactions (redness, slight swelling) may occur; systemic effects are rarely reported in research settings.
No melanotropic effects: Unlike full α-MSH, KPV does not affect melanocyte activity or skin pigmentation.

Complementary strategies for optimizing inflammatory balance.

Anti-inflammatory diet: Emphasize whole foods, omega-3 fatty acids, polyphenols, and minimize processed foods and refined sugars.
Stress management: Chronic stress elevates inflammatory markers; incorporate stress-reduction practices (meditation, yoga, adequate sleep).
Physical activity: Regular moderate exercise supports healthy inflammatory balance; avoid overtraining which can increase inflammation.
Sleep optimization: Prioritize 7–9 hours of quality sleep nightly to support immune regulation and inflammatory homeostasis.
Gut health: Support microbiome diversity through probiotic-rich foods and adequate fiber intake, particularly relevant for inflammatory bowel conditions.

General subcutaneous guidance from clinical best-practice resources.

Clean the vial stopper and skin with alcohol; allow to air dry completely.
Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue.
Withdraw the needle smoothly and apply gentle pressure with a clean alcohol swab (do not rub the site).
Rotate sites systematically using a pattern (e.g., alternating between right/left abdomen, right/left thigh) to avoid lipohypertrophy and maintain consistent absorption.
Preferred sites: abdomen (at least 2 inches from navel), anterior/lateral thigh, or outer upper arm (if self-administration is performed).

This content is intended for therapeutic educational purposes only and does not constitute medical advice, diagnosis, or treatment. KPV is a research peptide not approved by regulatory agencies for human therapeutic use. Consult qualified healthcare professionals before beginning any peptide protocol. This information is provided for educational and research reference purposes only.

Journal of Pharmaceutical Drug Delivery Research (2022)

— Pawar K. et al: KPV as an α-MSH fragment retains potent anti-inflammatory activity without melanotropic side effects

Int J Mol Sci (2024)

— Brozska T. et al: α-MSH and related tripeptides: modulation of colitis, inflammation, and melanocortin receptors

Gastroenterology (2008)

— Dalmaso G. et al: PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation in DSS colitis models

Innerbody Research (2025)

— KPV peptide benefits, safety, and administration routes; subcutaneous application for systemic research

Peptides.org Guide (2023)

— KPV measurement reference and research guidance: 200–400 mcg subcutaneously once daily for inflammation and wound healing

Bachem (Peptide Handling Guidelines)

— Long-term peptide stability best achieved in lyophilized form at ≤ −15 °C; avoid extended storage in solution

PeptideSciences (Storage Guidelines)

— Lyophilized peptides stable for short-term at 4 °C, long-term at −20 °C; prepared solutions refrigerated up to ~30 days

Johns Hopkins Arthritis Center

— Subcutaneous technique guidance: site preparation, needle angle (45–90°), and site rotation